Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
June 4, 2021

Coronavirus company news summary – ICMR approves Abbott’s home-based rapid antigen test kit – iXensor launches a fully digitised PixoTest Covid-19 rapid test

By Chloe Kent

The Indian Council of Medical Research (ICMR) has approved Abbott‘s PanBio Covid19 Antigen Test Device, the second Covid-19 test kit designed for home use to be approved by ICMR. The device received provisional approval till the 5 of July this year, after which the business will announce the price of the kit.

Eurofins Technologies has announced the unveiling of its GSD NovaType III SARS-CoV-2 RT-PCR test, which is designed for the rapid detection of Covid-19 variants of concern. The test identifies relevant mutations E484Q, E484K, and L452R in a combined reaction to the simultaneous discrimination of E484 variant of the S gene. These mutations have been found to reduce the efficacy of some vaccines and have reported increased transmissibility of the virus.

iXensor, a medical device company and a mobile health pioneer, has announced that its PixoTest POCT Covid-19 antigen test has received the European CE-IVD mark. The fully digitised screening solution can deliver results in just 15 minutes, and consists of a rapid antigen test, a website, and a digital health and admin app.

Related Companies

Content from our partners
“Everything is custom”: Behind the scenes of medical wire solutions
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU